CSANZ 2020

Stuart Cook

National Heart and Lung Institute, UK

Dr Cook grew up in Kenya, went to high school at St Edward’s, Oxford and studied medicine at St Bartholomew’s Medical School, London. He did a PhD at the National Heart and Lung Institute, UK and a Postdoctoral Fellowship at Harvard. He trained in cardiology and sub-specialized in cardiac MRI. He is Professor at Imperial College, London and Duke-NUS. His team helped define the central role of titin in dilated cardiomyopathy and developed a gene-based test for inherited cardiac conditions that was commercialised by Illumina and is now used in clinical practice worldwide. His group discovered a critical role for the IL11 cytokine in fibrosis, inflammation and tissue regeneration. He is a co-founder of Enleofen, a spin-out biotechnology company that developed first-in-class antibody therapeutics against IL11. Enleofen’s therapeutic platform was acquired by Boehringer Ingelheim in the largest Biotechnology deal from Singapore in late 2019. The overarching goal of his research is to understand cardiometabolic disease mechanisms and to translate basic science discoveries to healthcare.

Back to speakers